Top

Published in:

01-05-2011 | Preclinical study

RETRACTED ARTICLE: Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin

Authors: Steven M. Hill, Chi Cheng, Lin Yuan, Lulu Mao, Ralf Jockers, Bob Dauchy, Tripp Frasch, David E. Blask

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Abstract

Serum melatonin (MLT) levels have been reported to diminish significantly by the 5th and 6th decades of life as the incidence of breast cancer increases. Given MLT’s anti-cancer activity, we hypothesize that age-related decline in pineal MLT production leads to enhanced breast cancer development and growth as women age. In this study, we sought to determine whether the growth of tissue-isolated mammary tumors in young, adult, and old female Buffalo rats relates to the age-related changes in MLT and its MT1 receptor. Significant decreases in the peak nighttime serum MLT levels were observed in old as compared to adult and young rats. Significantly diminished nighttime and early morning levels of MT1-melatonin receptors were observed in uteri from old rats compared to adult and young rats. Growth rates in transplanted, tissue-isolated, carcinogen-induced mammary tumors are significantly increased in old rats as compared to adult or young rats. The growth-suppressive actions of exogenous MLT are diminished in old rats compared to adult and young rats. This decrease in tumor response correlates with reduced expression of the MT1 receptor in old as compared to young and adult rats. Thus, enhanced mammary tumor growth is associated with old age and diminished levels of MLT and MT1 receptor during old age, resulting in reduced sensitivity to exogenous MLT. Finally, our studies demonstrate that the tissue-isolated tumor model is viable model system in which to study the role of aging on breast cancer growth.

Mangus K (1982) Trends in cancer incidence: causes and practical implications. Hemisphere, Washington, D.C

Balducci L (2005) Epidemiology of cancer and aging. J Oncol Manag 14:47–50PubMed

Newell GR, Spitz MR, Sider JG (1989) Cancer and age. Semin Oncol 16:3–9PubMed

Waldhauser F, Dietzel M (1985) Daily and annual rhythms in human melatonin secretion; role in puberty control. Ann NY Acad Sci 453:205–214CrossRefPubMed

Cassone VM (1992) The pineal gland influences rat circadian rhythms in constant light. J Biol Rhythms 7:27–35CrossRefPubMed

Iguchi H, Kato K, Ibayashi H (1982) Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 55:27–35CrossRef

Blask DE, Hill SM, Orstead KM, Massa JS (1986) Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7, 12 dimethylbenzantrhacene (DMBA)-induced mammary tumorigenesis. J Neural Transm 67:125–138CrossRefPubMed

Blask DE, Pellitier DB, Hill SM, Massa J (1991) Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of the antiestrogenic mechanisms in vivo. J Cancer Res Clin Oncol 117:526–534CrossRefPubMed

Shah PN, Mhatre MC, Kurhan LS (1984) Effects of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res 44:3403–3407PubMed

10.

Hill SM, Blask DE (1988) Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 48:6121–6126PubMed

11.

Molis TM, Spriggs LS, Hill SM (1994) Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 8:1683–1690

12.

Ram PT, Kiefer T, Sliverman M, Song Y, Brown GM, Hill SM (1998) Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors. Mol Cell Endocrinol 141:53–64CrossRefPubMed

13.

Molis TM, Spriggs LS, Jupiter Y, Hill SM (1994) Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer. J Pineal Res 18:93–103CrossRef

14.

Dauchy RT, Sauer LA (1986) Preparation of “tumor-isolated” rat tumors for perfusion: a new surgical technique that preserves continuous blood flow. Lab Animal Sci 36:678–684

15.

Sauer LA, Nagel WO, Dauchy RT et al (1986) Stimulation of tumor growth in adult rats in vivo during acute fast. Cancer Res 46:3469–3475PubMed

16.

Douchy RT, Blask DE, Sauer LA, Brainard GC, Grause JA (1999) Dim light during darkness stimulates tumor progression by enhancing tumor fatty acid uptake and metabolism. Cancer Lett 144:131–136CrossRef

17.

Vaughan MK, Vaughan GM, Reiter RJ, Blask DE (1976) Influence of melatonin, constant light, or blinding on reproductive system of gerbils (Meriones unguiculatus). Experentia 32:1341–1342CrossRef

18.

Niklowitz P, Bocker TM, Lerchl A (1996) Afternoon injection of melatonin in the Djungarian hamster Phodous sungorus: long lasting sex-specific effects and influence of acute treatment on the endogenous pineal melatonin rhythm. J Pineal Res 21:231–238CrossRefPubMed

19.

Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM (2002) MT1 melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 192:147–156CrossRefPubMed

20.

Teplitzky SR, Kiefer TL, Cheng Q, Blask DE, Hill SM (2001) Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis retinoic acid. Cancer Lett 168:155–163CrossRefPubMed

21.

Melancon K, Cheng Q, Kiefer TL, Teplitzky SR, Hill SM (2005) Regression of NMU-induced mammary tumors with the combination of melatonin and 9-cis retinoic acid. Cancer Lett 227:39–48CrossRefPubMed

22.

Reiter RJ, Craft CM, Johnson JE, King TS, Richardson BA, Vaughan GM, Vaughan MK (1981) Age-associated reduction in nocturnal melatonin levels in female rats. Endocrinology 109:1295–1297CrossRefPubMed

23.

Rendakov NL, Tiutiunnik NN, Viogradova IA (2006) Effects of age, different light conditions, melatonin and epitalon on lysosomal proteinase activity in the liver and kidneys of rats. Adv Gerontol 19:72–78PubMed

24.

Zeitzer JM, Duffy JF, Lockley SW, Dijk DJ, Czeisler CA (2007) Plasma melatonin rhythms in young and older humans during sleep, sleep deprivation, and wake. Sleep 30:1437–1443CrossRefPubMedPubMedCentral

25.

Bondy SC, Sharman EH (2007) Melatonin and the aging brain. Neurochem Int 50:571–580CrossRefPubMed

26.

Lai L, Yuan L, Cheng Q, Dong C, Mao L, Hill SM (2008) Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines. Breast Cancer Res Treat (epub)

27.

Sanchez-Hidalgo M, Guerrero Montavez JM, Carrascosa-Salmoral MD, Naranjo-Gutierrez MD, Lardone PJ, a Romero CA (2009) Decreased MT1 and MT2 melatonin receptor expression in extrapineal tissues of the rat during physiological aging. J Pineal Res 46:29–35CrossRefPubMed

Title: RETRACTED ARTICLE: Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin
Authors: Steven M. Hill
Chi Cheng
Lin Yuan
Lulu Mao
Ralf Jockers
Bob Dauchy
Tripp Frasch
David E. Blask
Publication date: 01-05-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0958-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer

Prognostic significance of micrometastasis and isolated tumor cells in the sentinel lymph node

Identification of immunodominant HLA-B7-restricted CD8+ cytotoxic T cell epitopes derived from mammaglobin-A expressed on human breast cancers

Biomarkers of PARP inhibitor sensitivity

Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1–4 years: N-SAS BC 03

Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer